Evidence map›Paper›PMID 42512341›Full record

ArticleCancers2026

A Novel Bruton's Tyrosine Kinase Inhibitor Suppresses Pancreatic Neuroendocrine Neoplasms Progression via ATF3-Induced Ferroptosis.

Ping Hu, Lijun Yan, Bingyan Xue, Na He, Jianqiang Qian, Xintong Lu, Min Liu, Yanling Xu, Xu Han, Mujie Ye and 1 more

Abstract read

In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ping HuDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Lijun YanDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Bingyan XueDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Na HeDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Jianqiang QianSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211100, China.

Xintong LuDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Min LiuDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Yanling XuDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Xu HanDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Mujie YeDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-5363-2752

Qiyun TangDepartment of Neuroendocrine Tumor, the First Affiliated Hospital with Nanjing Medical University, Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing 210029, China.

Funding

National Natural Science Foundation of China 82303453National Natural Science Foundation of China 82373180

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

activating transcription factor 3Bruton’s tyrosine kinase inhibitorsferroptosispancreatic neuroendocrine neoplasms

Identifiers

PMID42512341

DOI10.3390/cancers18142277

PMCPMC13407139

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.